Cytiva Official site

FF High Performance (FFHP)

Nitrocellulose membrane for immunochromatography used in the manufacturing of in vitro diagnostic reagents, suppressing lot-to-lot variation and within-lot variation.

●Improvement of reproducibility in signal intensity/capillary flow time   - Suppression of inter-lot variation       Signal intensity: Below 10% CV       Capillary flow time: Below 10% CV   - Suppression of intra-lot variation       Signal intensity: Below 10% CV       Capillary flow time: Below 10% CV ●Cost reduction in assay optimization through improved reproducibility In in vitro diagnostics, there is a demand for the development of test kits that can reliably and quickly detect target molecules contained in liquids such as water, urine, blood, and saliva, and provide results. FF HP is a nitrocellulose membrane optimized for lateral flow assays. By reviewing the manufacturing process and making improvements such as a powder-free surface that is crucial for sharp judgment lines, high reproducibility in immunoassay tests has been achieved. FFHP and FFHP Plus use different surfactants. FFHP Plus Thick is a new series with a thicker membrane that uses the same surfactant as FFHP Plus (approximately 235 µm thick including backing).

Related Link - https://www.cytivalifesciences.co.jp/catalog/1781.…

basic information

Laminating Customization Service We offer a customization service for laminating using nitrocellulose membranes and backing sheets handled by our company. If you are interested, please contact our Bio Direct Line (TEL: 03-5331-9336, e-mail: Tech-JP@cytiva.com).

Price range

Delivery Time

Applications/Examples of results

For more details, please feel free to contact us.

Recommended products

Distributors

Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.